Enhabit (EHAB) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Net service revenue rose 1.9% year-over-year to $264.8 million for Q1 2026, driven by 6.2% growth in Hospice and 0.6% in Home Health.
Net income attributable to shareholders increased 7.9% to $19.2 million, with EPS at $0.37 (basic) and $0.36 (diluted).
A merger agreement was signed in February 2026; closing is expected in Q2 2026, after which shares will be delisted.
No branch closures occurred in Q1 2026, and none are anticipated for the remainder of the year.
Financial highlights
Gross margin was $130.6 million, up 0.7% year-over-year.
General and administrative expenses fell 10.0% to $96.7 million, aided by a $17.7 million litigation settlement gain.
Adjusted EBITDA was $24.4 million, down from $26.6 million in Q1 2025.
Operating income increased 84.3% to $29.3 million, reflecting lower G&A expenses.
Effective tax rate dropped to 13.5% from 28.7% due to changes in valuation allowance.
Outlook and guidance
The proposed 2027 Hospice Rule would increase payments by 2.4% starting October 2026, expected to benefit revenue.
Management expects continued compliance with debt covenants but notes ongoing monitoring is required.
Latest events from Enhabit
- Shareholders to vote on $13.80 per share cash merger, with board unanimous in support.EHAB
Proxy filing - Shareholders to vote on a $13.80/share cash merger, with board unanimous support and appraisal rights.EHAB
Proxy filing - Pending merger with Kinderhook Industries follows a year of revenue growth and operational improvement.EHAB
Proxy Filing - Revenue and EBITDA rose, leverage fell, and a merger is pending.EHAB
Q4 2025 - Acquisition by Kinderhook Industries prompts shareholder vote and transition to private ownership.EHAB
Proxy Filing - Kinderhook Industries to acquire Enhabit; shareholders to receive $13.80 per share upon closing.EHAB
Proxy Filing - Pending acquisition will take the company private, subject to shareholder approval in 2026.EHAB
Proxy Filing - Q3 2025 delivered higher revenue, record hospice growth, and improved leverage and profitability.EHAB
Q3 2025 - New payer contracts drive growth and offset UnitedHealthcare exit, with strong hospice and cost control.EHAB
2024 Wells Fargo Healthcare Conference